Under the deal, Peptris Technologies is licensing PEPR124 (RT001), a preclinical-stage drug, to Revio Therapeutics for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback